Rotavirus is the most common cause of severe childhood gastroenteritis worldwide, leading to an estimated 453 000 deaths among children ,5 years old annually. 1 In 2006, the World Health Organization (WHO) recommended the use of rotavirus vaccines for countries in the Americas and Eastern Europe on the basis of good vaccine efficacy and safety data from these regions. In 2009, after trials demonstrated the efficacy of rotavirus vaccines in Asia and Africa, WHO expanded the recommendation to all children worldwide. 2 Since 2006, some 30 countries worldwide have introduced rotavirus vaccines into their routine immunization program, with introductions mostly in high-and middleincome countries with low diarrhearelated mortality. Vaccine introduction in these early adopter countries has markedly reduced the burden of severe childhood gastroenteritis, including diarrhea mortality in Brazil and Mexico where this has been specifically examined. [3] [4] [5] In clinical trials, the efficacy of rotavirus vaccines against severe rotavirus disease has been lower in low-income, high-child-mortality countries compared with high-and middle-income countries with lower child mortality [6] [7] [8] . This disparity in vaccine performance may reflect factors that impair vaccine take or immune responses in highmortality populations, such as circulating maternal antibodies, breast milk interference, concomitant enteric infections, oral polio vaccine interference, and undernutrition. 9 Despite lower effectiveness in high-mortality settings, rotavirus vaccines are likely to have their highest life-saving potential in these regions where .90% of deaths from rotavirus diarrhea occur. 10 However, the efficacy of rotavirus vaccines against rotavirus mortality could not be examined in clinical trials because of the very large sample size required.
Consequently, monitoring the impact of rotavirus immunization against diarrhea deaths during routine use in national immunization programs will be critical for better understanding the full potential of these vaccines.
In Mexico, substantial declines in childhood deaths from diarrhea have been documented since the national introduction of rotavirus vaccine during 2007. During 2008-2010, diarrhearelated deaths among children ,5 years old decreased by 46% relative to prevaccine levels from 2003 through 2006. 11 However, because of year-to-year variations in diarrhea rates, ongoing evaluation is necessary to confirm that the observed reductions early after the introduction of vaccine are sustained, thus providing stronger support for vaccine effect rather than secular changes. In addition, potential regional differences in vaccine impact have not been previously evaluated. The level of economic development and health care infrastructure differs between the various states of Mexico: the northern and central states are more developed compared with the southern states. This heterogeneity in economic development provides an opportunity to assess whether differences in vaccine impact on diarrhea deaths exist by region.
The primary objectives of this analysis were to determine if the reductions in diarrhea deaths previously documented during 2008-2010 were sustained during 2011 and to compare postvaccination trends in diarrhearelated mortality in the lesser developed southern region of Mexico with those in the more developed northern and central regions. The high quality of Mexico' s death registration data and the heterogeneity in development between regions provided a suitable setting to examine regional differences of the impact of the rotavirus vaccine on diarrhea-related mortality.
METHODS

Diarrhea-Related Deaths
We obtained numbers of diarrhearelated deaths among Mexican children from the National Institute of Statistics, Geography, and Informatics, which gathers and codes death certificates for children ,5 years of age. Data were accessed through the National System for Health Informatics and collected for the period 5 Two doses given at ages 2 and 4 months were recommended. Because surveys of rotavirus vaccine coverage are not available for Mexico, we relied on administrative coverage data kept by CENSIA on the number of doses given (either 1 or 2 doses) and the population served by CENSIA. 14 A crude estimate of rotavirus vaccine coverage was calculated by dividing the number of doses administered during 2010 by the cohort of infants eligible to receive vaccine through CENSIA.
Data Analysis
Trends of diarrhea-related mortality were examined over the entire surveillance period (from July 2002 through December 2011). Median rates of diarrhea-related death for each surveillance year were calculated by using corresponding population estimates for Mexico from the National Population Council. We compared region-specific diarrhea mortality rates and absolute reductions in number of diarrhea deaths before (2003) (2004) (2005) (2006) 
RESULTS
Socioeconomic Indicators
An analysis of the mean indicators of development by region in Mexico indicates that the southern region has a higher under-5 mortality rate and lower gross domestic product per capita and Human Development Index compared with the northern and central regions (Table 1) .
Vaccine Coverage
On the basis of CENSIA administrative data, 3 830 932 second rotavirus vaccine doses were administered to a target population of 4 677 341 children ,5 years of age in Mexico during 2010, for a vaccine coverage of 82% (Table 2) . Two-dose vaccine coverage was $68 across the 3 age groups and regions. In general, coverage was highest among children ,24 months of age and in the northern states of Mexico (Table 3) .
Diarrhea-Related Deaths
Overall Trends
Before nationwide introduction of the rotavirus vaccine in 2007, diarrhea deaths among children ,5 years followed a predictable seasonal pattern, with almost two-thirds of all deaths occurring from December to May (Fig 1) . Nearly 67% of the deaths were among children #11 months of age, whereas 23% and 10% were among those 12 to 23 months and 24 to 59 months of age, respectively. After introduction of the vaccine, there was a clear flattening of the winter peak in diarrhea-related mortality compared with previous years. During 2008, the first year after vaccine introduction, reduction in diarrhea deaths was most prominent among infants, the only age group that would have been vaccinated. After 2009, a reduction in deaths was observed in the 12-to 23-month age group and was sustained to the end of 2011.
Prevaccine (2003-2006) Versus Postvaccine (2009-2011) Years
When comparing the number of diarrhea-related deaths by age group in the pre-and postvaccine years, reductions in diarrhea mortality were observed across all age groups in Mexico ( Table 2 ). The greatest relative reductions in rates of diarrhea-related deaths were seen among children ,24 months of age. Although the relative reduction was lower among children $24 months 
DISCUSSION
Our findings of significant reductions in diarrhea death of ∼50%, which were sustained for 4 continuous years, provide a Prevaccine and postvaccine values are the median of the yearly sums of diarrhea-related death for each period and for each age group. b Because the Ministry of Health at times delivers vaccine to a larger operative region than planned, coverage in certain age groups for 2010 exceeds 100%. c P values were calculated with the use of x 2 tests. Sum-rank test showed no differences in rate reductions across regions (P . .8).
strong suggestive evidence of the beneficial effects of rotavirus vaccination against fatal rotavirus disease in Mexico. Moreover, the similarity in reductions in the lowest and highest income sectors of Mexico indicates equitable distribution of vaccine and that the vaccine is reaching children at the highest risk of dying in this country. Before rotavirus vaccine introduction, diarrheal disease was estimated to cause ∼5% of deaths among children ,5 years of age in Mexico 15 and ∼3000 deaths annually. 16, 17 Combining regional reductions, we estimated an annual reduction of ∼1000 childhood diarrhea deaths in Mexico after vaccine introduction. In addition, largely because of substantially greater baseline rates of diarrhea mortality seen in the south, the number of deaths prevented per population was highest in this region.
Rotavirus has been confirmed to be the single most important cause of severe diarrhea among children worldwide, accounting for ∼40% of all hospitalizations for diarrhea. 1, 18 However, given the inherent challenges associated with laboratory confirmation of diarrhearelated deaths, few studies have sought an enteric pathogen from children who died of diarrhea. Thus, the global burden of rotavirus deaths has been estimated by using the assumption that the prevalence of rotavirus among children hospitalized with severe diarrhea approximates the prevalence of rotavirus among those children who die of diarrhea. The sustained reductions in diarrhea deaths of 44% to 56% among children ,5 years old after the introduction of rotavirus vaccine in Mexico provides a "probe study" confirming the validity of this critical assumption.
Although previous studies have revealed that efficacy against rotavirus disease of any severity varies by socioeconomic status, 10 When interpreting our findings, careful consideration of the variability in health determinants within regional groupings is also warranted. For example, vaccine coverage and effect, level of development and access to care, and the relative importance of rotavirus as a cause of death may differ significantly across regions and could have influenced our results. Despite these caveats, the robust and uniform reduction in diarrhea deaths evident throughout Mexico is encouraging and suggests vaccine success.
CONCLUSIONS
In summary, our assessment revealed large and consistent reductions in childhood diarrhea-related death across all 3 regions of Mexico, with distinct levels of development, which are likely related to rotavirus vaccine introduction. These findings indicate equitable vaccine delivery to children with varying risk of mortality and reaffirm the beneficial effects of rotavirus vaccination against fatal diarrheal disease. Our results additionally support the WHO recommendation for rotavirus vaccine introduction in high-mortality, resource-limited settings. Over the next few years, as rotavirus vaccines are introduced in these regions, continued monitoring of diarrhea-related deaths, ongoing rotavirus surveillance, and case-control vaccine effectiveness studies are essential to precisely quantify the impact of rotavirus vaccination worldwide.
